Serina Therapeutics, Inc. (SER): debt financing — AgeX Therapeutics draws $500k under secured note with Juvenescence

Serina Therapeutics, Inc.

Drew $500,000 under Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited on August 22, 2023.
Repayment date for outstanding principal is February 14, 2024.
Terms previously summarized in May 12, 2023 10-Q and June 8, August 4, 2023 8-K filings.

item 2.03 item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.

Instrument: convertible notes
Principal: $500,000
Counterparty: Juvenescence Limited
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On August 22, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited. The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.

View on SEC.gov

89 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-030212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.